Will a new lung drug clash with common medicines?
NCT ID NCT07744386
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial is testing whether an experimental drug called CHF10196 changes how the body processes two other medications: dabigatran (a blood thinner) and rosuvastatin (a cholesterol drug). Healthy male volunteers will take these drugs alone and then together with CHF10196, and researchers will measure drug levels in the blood to see if there is any interaction. The goal is to ensure that CHF10196 can be safely used alongside common treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CHF10196, dabigatran etexilate, and rosuvastatin
- What this could lead to
- If CHF10196 does not interfere with these drugs, it could be safely combined with common medications in future treatments.
- What could go wrong
- This is an early-phase study in a small group of healthy men, so results may not apply to patients or predict real-world outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY MALE VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit (CRU) Limited
Leeds, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.